­
­
­
­

Inventi Impact - Biomedical Analysis

Patent Watch

  • Fibrous protein fusions and use thereof in the formation of advanced organic/inorganic composite materials

    The claimed invention provides a fusion polypeptide comprising a fibrous protein domain and a mineralization domain. The fusion is used to form an organic-inorganic composite. These organic-inorganic composites can be constructed from the nano- to the macro-scale depending on the size of the fibrous protein domain used. The composites can also be loaded with other compounds (e.g. dyes, drugs, enzymes) depending on the goal for the materials, to further enhance function. This can be achieved during assembly of the materials or during the mineralization step in materials formation.

  • Cationic end-capped siloxane prepolymer for reduced cross-link density

    The present invention relates to hydrophilic dicationic siloxane prepolymers with one polymerizable vinyl moiety instead of two polymerizable vinyl moieties, resulting in contact lenses and/or biomedical devices with reduced cross-link density and modulus without detracting from other properties.

  • Methods for multi-material stereolithography

    Methods and systems of stereolithography for building cost-efficient and time-saving multi-material, multi-functional and multi-colored prototypes, models and devices configured for intermediate washing and curing/drying is disclosed including: laser(s), liquid and/or platform level sensing system(s), controllable optical system(s), moveable platform(s), elevator platform(s), recoating system(s) and at least one polymer retaining receptacle. Multiple polymer retaining receptacles may be arranged in a moveable apparatus, wherein each receptacle is adapted to actively/passively maintain a uniform, desired level of polymer by including a recoating device and a material fill/remove system. The platform is movably accessible to the polymer retaining receptacle(s), elevator mechanism(s) and washing and curing/drying area(s) which may be housed in a shielded enclosure(s). The elevator mechanism is configured to vertically traverse and rotate the platform, thus providing angled building, washing and curing/drying capabilities. A horizontal traversing mechanism may be included to facilitate manufacturing between components of SL cabinet(s) and/or alternative manufacturing technologies.

  • Spatial resolution determination for cardiac mapping

    A non-contact cardiac mapping method is disclosed that includes: (i) inserting a catheter into a heart cavity having an endocardium surface, the catheter including multiple, spatially distributed electrodes; (ii) measuring signals at the catheter electrodes in response to electrical activity in the heart cavity with the catheter spaced from the endocardium surface; and (iii) determining physiological information at multiple locations of the endocardium surface based on the measured signals and positions of the electrodes with respect to the endocardium surface. Related systems and computer programs are also disclosed.

  • Enzyme sensor with a cover membrane layer covered by a hydrophilic polymer

    The present disclosure relates to an improved enzyme sensor comprising a cover membrane layer of a porous polymeric material, the outer surface and pore mouths of at least one face of the porous polymeric material being covered by a hydrophilic polymer. The sensor is useful determining the presence or amount of biological analytes, e.g., glucose, lactate, creatine, creatinine, etc.

  • Plasma incising device including disposable incising tips for performing surgical procedures

    An apparatus for performing surgery using plasma is described. The apparatus includes a plasma generating unit, a plasma wand and a foot pedal. The plasma wand further includes a disposable tip which may be removed and replaced for each surgical procedure, so as to maintain operating sterility.

  • Medical probes for creating and diagnosing circumferential lesions within or around the ostium of a vessel

    The present inventions provide assemblies, probes, and methods for creating circumferential lesions in tissue, e.g., the tissue within or around the ostium of a vessel. An ablation probe with an ablative structure can be placed in contact within or around the ostium of the vessel. A diagnostic probe can be introduced through a lumen within the ablation probe and inserted into the vessel. The energy can be provided to the ablative structure to create a circumferential lesion within or around the ostium of the vessel, and the diagnostic structure can be used to diagnose the tissue to determine whether the circumferential lesion can be properly created.

  • BIOACTIVE AGENT FOR BONE TISSUE ENGINEERING

    Inventors have discovered a method for inducing bone formation in a patient in need thereof comprising administering an effective amount of benzoyladenosine-3',5'-cyclic monophosphate (6-Bnz-cAMP) to the patient. Systems for bone tissue engineering, comprising a polymer-based scaffold, such as a PLAGA scaffold and an effective amount of 6-Bnz-cAMP are also disclosed herein.

  • Injectable Hydrogel Filaments For Biomedical Uses

    Described herein are apparatus, compositions, systems and associated methods to occlude structures and malformations with radiopaque hydrogel filaments with delayed controlled rates of expansion permitting the repositioning of the device once inside the structure or malformation. Further described is a device for implantation in an animal comprising a difunctional, low molecular weight ethylenically unsaturated shapeable macromer; an ethylenically unsaturated monomer; and a radiopaque element, wherein said device contains no support members. Methods of forming such devices are also disclosed.

  • USE OF POROUS HOLLOW-FIBER MEMBRANE FOR PRODUCING CLARIFIED BIOMEDICAL CULTURE MEDIUM

    Use of a porous hollow fiber membrane for producing a clarified biomedical culture medium by a method including a filtration step of distributing a biomedical culture medium over the porous hollow fiber membrane, a tube wall of the hollow fiber membrane being constituted of a blend of a hydrophobic polymer and polyvinylpyrrolidone. A content of the polyvinylpyrrolidone is not lower than 0.2% by mass and not higher than 3% by mass relative to a total mass of the porous hollow fiber membrane, and, when the tube wall is divided in a membrane-thickness direction equally into three regions, a content of the polyvinylpyrrolidone in an outer circumferential region including an outer face is higher than a content of the polyvinylpyrrolidone in an inner circumferential region including an inner face, and an average pore size in the inner face is larger than an average pore size in the outer face.

  • HYDROGEL TISSUE ADHESIVE FORMED FROM AMINATED POLYSACCHARIDE AND ALDEHYDE-FUNCTIONALIZED MULTI-ARM POLYETHER

    A hydrogel tissue adhesive formed by reacting an aminated polysaccharide with a water-dispersible, aldehyde-functionalized multi-arm polyether is described. The hydrogel tissue adhesive may be useful as a general tissue adhesive and sealant for medical and veterinary applications such as wound closure, supplementing or replacing sutures or staples in internal surgical procedures such as intestinal anastomosis and vascular anastomosis, tissue repair, ophthalmic procedures, drug delivery, and to prevent post-surgical adhesions. Additionally, due to the presence of the aminated polysaccharide, the hydrogel tissue adhesive may also promote wound healing and blood coagulation, and provide antimicrobial properties.

  • REPLACEABLE MICRONEEDLE CARTRIDGE FOR BIOMEDICAL MONITORING

    A replaceable microneedle array for a biomedical monitor is disclosed. The microneedle array includes a plurality of moveable microneedles coated with at least one chemical sensing material coupled with a porous material. The microneedle array also includes a substrate defining wells to house the microneedles. The microneedle array further includes at least one restoring spring element coupled between each microneedle and the substrate such that each of the plurality of microneedles is held at least partially in an associated well.

  • METHODS AND DEVICES FOR TISSUE COLLECTION AND ANALYSIS

    The present invention is directed to methods and devices for tissue collection and analysis, and particularly to methods and devices for collecting, preserving and analyzing biopsy samples. In one aspect, a method for collecting a tissue sample includes disposing a collection device proximate and/or within a tissue, such as of a body, drawing in at least a portion of the tissue into the collection device, adhering the at least a portion of the tissue to at least a portion of the collection device and separating the sample and collection device from the remainder of the tissue and/or body. In general, the method of adhering the tissue sample to the collection device may also preserve the tissue sample, such as, for example, by altering the temperature of the tissue sample. In one embodiment, the method of adhering the tissue sample to the collection device includes lowering the temperature of the collection device and thus the tissue sample such that the tissue sample may adhere to the collection device and may also be preserved against degradation.

  • Meniscus Prosthetic Device Selection and Implantation Methods

    Methods of selecting and implanting prosthetic devices for use as a replacement meniscus are disclosed. The selection methods include a pre-implantation selection method and a during-implantation selection method. The pre-implantation selection method includes a direct geometrical matching process, a correlation parameters-based matching process, and a finite element-based matching process. The implant identified by the pre-implantation selection method is then confirmed to be a suitable implant in the during-implantation selection method. Methods of implanting meniscus prosthetic devices are also disclosed.

  • Sonic resonator system for use in biomedical applications

    Disclosed herein is a sonic resonator system and a method of using the system which is useful in therapeutic, cosmetic or aesthetic, diagnostic, exploratory and other medical procedures, particularly where a relatively non-invasive procedure is needed. The sonic resonator system and its method of use provide a controllable high intensity sonic impulse, which may be in the form of a compression or rarefaction wave applied to a given target tissue or anatomical structure, to cause a significant therapeutic or other physiological effect.

  • OXYGEN SENSOR

    The present invention generally relates to systems and methods for determining oxygen in a sample, or in a subject. In one aspect, the present invention is generally directed to an article exhibiting a determinable feature responsive to oxygen, such as oxygen-sensitive particles. The particles may exhibit a determinable change with a change in oxygen concentration, and such particles can accordingly be used to determine oxygen. For example, in one set of embodiments, the particles may be at least partially coated with a protein, such as hemoglobin, that is able to interact with oxygen. In some cases, the protein may aggregate under certain conditions (e.g., under relatively low oxygen concentrations), and such protein aggregation may be used, for example, to cause the particles to become aggregated, which can be determined in some way. In some cases, such aggregation may be irreversible; i.e., the degree of aggregation corresponds to the most extreme oxygen concentrations that the proteins were exposed to. Such articles may be used, for example, to determine oxygen within a sample, or within a subject, such as a human subject. For instance, the article may be formed as a skin patch, or administered to the skin of a subject, e.g., on the surface of the skin, within the dermis or epidermis, etc., to determine oxygen within the subject.

  • NANOSCALE SENSORS

    A nanocoaxial sensor includes an outer conductor, an inner conductor, a dielectric material disposed between the outer and inner conductors, a nanocavity sized to allow target species to enter the nanocavity between the outer and inner conductors, and an active sensing element immobilized within the nanocavity on at least one of the inner or outer conductors. The active sensing element is adapted to selectively capture the at least one of the target species.

  • BIOREACTORS FOR TISSUE ENGINEERING

    Bioreactors and methods of using them to produce tissue engineered products or culture cells are disclosed, and more particularly on the development of a tissue and cell culture method based upon an expanded bed bioreactor in which an initial resting bed of particles on which or in which cells are attached, encapsulated or immobilised have a fluid passed upwards through the bed to form an expanded bed in which the fluid acts to separate the particles, i.e. under plug flow conditions to enable the relative positions of the particles to be maintained during the step of culturing the cells to form tissue and helps to reduce collisions between particles and turbulent flow or convective mixing.

  • Analysis System And Computer Implemented Method For Analyzing Biological Samples

    Analysis system and computer implemented method for analyzing biological samples are disclosed. The system has at least one analyzer for performing an analysis and a decision unit being operable to determine in response to the receipt of the analysis request whether results obtained from performing the analysis on the sample indicated in the analysis request are valid. This determination is executed by retrieving the meta information assigned to the sample and by applying the at least one condition on the meta information and wherein the at least one applied condition has at least a condition on whether the sample allows a valid analysis on the sample, and wherein the decision unit returns the decision that the analysis exercised on the indicated sample will return a valid result in case the conditions of the condition set are met by the sample.

  • ANALYTIC METHODS OF TISSUE EVALUATION

    The present invention generally relates to methods and systems for (i) skin assessment based on the utilization of bioimpedance and fractional calculus and implementation of methods for skin hydration assessment based on the utilization of bioimpedance and fractional calculus and systems thereof, (ii) an Opto-Magnetic method based on RGB and gray images data as "cone-rods" principles with enhanced qualitative and quantitative parameters for analyzing water based on Opto-Magnetic properties of light-matter interaction and systems thereof, and (iii) imaging and analyzing skin based on the interaction between matter and electromagnetic radiation and implementation of an Opto-Magnetic method with enhanced qualitative and quantitative parameters for imaging and analyzing skin based on Opto-Magnetic properties of light-matter interaction and systems thereof.

  • SUPERVISED PRINCIPAL COMPONENT ANALYSIS

    The invention provides a multivariate modeling method for quantitative analysis by supervised principal component analysis (SPCA). The method comprises: (a) designing a plurality of calibration samples wherein the desired variances are dominant or greatly enhanced; (b) producing a calibration data matrix using suitable mathematical pretreatment and truncation of the acquired NIR/Raman spectra of the calibration samples; (c) decomposing the matrix using PCA; (d) evaluating the score and loading matrices to ensure a genuine orthogonal relationship between scores of the desired latent variables in a two-dimensional principal component space 7; (e) generating a prediction matrix for quantitative prediction of unknown samples. This method does not require testing of calibration samples using a reference method. In addition, this method has high tolerance to variations in sample composition and manufacturing conditions.

  • Server for Integrated Pharmaceutical Analysis and Report Generation Service, Method of Integrated Pharmaceutical Manufacturing and Research and Development Numerical Analysis, and Computer Readable Recording Medium

    A web-based tool (as a server) for integrated pharmaceutical analysis and report generation service is provided in the present invention. The server can be used for numerical analysis and report generation for pharmaceutical manufacturing, research and development, and has advantages such as simple operation, complicated but fast calculation and professional report generation, and high accuracy. The server includes at least one pharmaceutical manufacturing and research and development numerical analysis system configured to perform different pharmaceutical manufacturing and research and development numerical analyses and generate different reports. Each of the at least one pharmaceutical manufacturing and research and development numerical analysis system includes an input module configured to receive, via a user interface, at least one of a template file and a backup file previously output by the server as at least one input file, wherein the at least one input file includes a plurality of data fields to provide corresponding data; at least one calculation module, each configured to execute a built-in pharmaceutical manufacturing and research and development numerical analysis calculation program, thereby automatically performing a pharmaceutical manufacturing and research and development numerical analysis calculation on at least one of the data of the at least one input file and on-line filled data; and an output module configured to generate at least one of a backup file and a report file as at least one output file based on the result of the pharmaceutical manufacturing and research and development numerical analysis calculation performed by the at least one calculation module and provide the at least one file via the user interface.

  • PURIFICATION OF VACCINIA VIRUSES USING HYDROPHOBIC INTERACTION CHROMATOGRAPHY

    The present invention relates to methods for purification of Vaccinia viruses (VV) and/or Vaccinia virus (VV) particles, which can lead to highly pure and stable virus preparations of predominantly biologically active viruses. The invention encompasses purifying a virus preparation in a sterilized way with high efficiency and desirable yield in terms of purity, biological activity and stability, aspects advantageous for industrial production.

  • TEST KIT AND METHOD FOR MEASUREMENT OF METALS IN BIOLOGICAL FLUIDS

    A test kit and a biomedical process is provided to estimate metals particularly non-transferrin bound iron levels (NTBI) in circulating body fluids particularly, serum. NTBI appears in serum when there is excess iron in the body. The method comprises of employing a signal generating moiety capable of complexing with iron that is a peptide like molecule having an iron binding site and also an optical signal generating functional group. The molecule is of microbial origin. The measurement is based on the alteration of optical characteristics of the probe molecule upon attachment of iron to its binding site on the molecule. Hence it generates a signal proportionate to the amount of iron available for binding and provides a direct estimate of free or unbound iron in the sample. According to this instant invention a rapid estimation method of NTBI in body fluids can be undertaken in an inexpensive way without the need of specialized expertise.

  • DRY ELECTRODE FOR BIOMEDICAL SIGNAL MEASURING SENSOR

    A dry electrode for biomedical signal measuring sensor includes a conductive sponge, a conductive fabric, and a thin metal film. The conductive fabric covers the whole conductive sponge, and the thin metal film is disposed on one face of the conductive fabric opposite to the conductive sponge. When using the dry electrode in measuring biomedical signal, it is not necessary to apply a conductive gel on a patient's skin, at where the biomedical signal is to be measured. Without the need of applying the conductive gel, the dry electrode is readily for measuring biomedical signal at any time and can be conveniently used in measuring signal over a long period of time without the problem of an attenuated signal due to gradually becoming dried conductive gel.

  • NON-INVASIVE BIOMEDICAL DETECTION AND MONITORING SYSTEMS

    The present disclosure relates to a non-invasive and continuous biomedical detections and non-invasive and continuous monitoring methods and devices for extracting and analyzing interstitial fluid extracted non-invasively and continuously from the skin of a subject comprising non-invasively electroporating the skin using a non pulsed voltage in combination with a pulsed voltage and applying negative pressure

  • NITRIC OXIDE-RELEASING PARTICLES FOR NITRIC OXIDE THERAPEUTICS AND BIOMEDICAL APPLICATIONS

    The presently disclosed subject matter relates to nitric oxide-releasing particles for delivering nitric oxide, and their use in biomedical and pharmaceutical applications.

  • SPATIAL IMAGING METHODS FOR BIOMEDICAL MONITORING AND SYSTEMS THEREOF

    A method for monitoring at least one biomedical characteristic is disclosed. A first microneedle coated with one or more regions of a chemical sensing material is illuminated. One or more digital images are captured of the first microneedle, wherein at least one of the one or more digital images is captured after the first coated microneedle has been actuated to penetrate a subject's skin. Pixel information is spatially extracted from the captured one or more images to define one or more pixel sample areas corresponding to the one or more regions of a chemical sensing material. One or more spectral characteristics are determined for each of the one or more pixel sample areas. The at least one biomedical characteristic is determined for each of the one or more pixel sample areas based on the determined one or more spectral characteristics for each of the one or more pixel sample areas.

  • URINE SAMPLE TESTING APPARATUS AND APPARATUS FOR PROCESSING MEASUREMENT RESULT OF URINE SAMPLE

    A urine sample testing apparatus comprises: a urine qualitative measuring section configured to acquire a measurement result for each of a plurality of urine qualitative measurement items; a urine sediment measuring section configured to acquire a measurement result for each of a plurality of urine sediment measurement items; an operation part that is operable by a user to specify a combination of one of the plurality of urine qualitativemeasurement items and one of the plurality of urine sediment measurement items; an information processing unit configured to determine whether or not a first measurement result of the urine sample obtained by the urinequalitative measuring section and a second measurement result of the urine sample obtained by the urine sediment measuring section have a predetermined relationship with respect to the urine qualitative measurement item and the urine sediment measurement item included in the specified combination.

  • IMMUNOGENIC COMPOSITIONS AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF

    The present invention relates to a method of inducing an immune response to a parasite utilizing an immunogenic composition comprising a glycosylphosphatidylinositol ("GPI") inositolglycan domain or its derivative or equivalent. The present invention is useful as a prophylactic and/or therapeutic treatment for microorganism infections of mammals such as parasite infections and particularly infection by Plasmodium species. The invention also provides a method of monitoring, or qualitatively or quantitatively assessing an immune response to a microorganism such as a parasite. More particularly, this aspect of the present invention is directed to assessing said immune response utilizing a GPI inositolglycan domain or its derivative or equivalent, which facilitates the qualitative and/or quantitative analysis of anti-GPI antibodies in a biological sample, the identification of unique specificities of antibodies, epitope specific screening or the rational design of immunogenic molecules and the generation, thereby, of functionally effective immunointeractive molecules.

  • Method and Device for Early Signal Attenuation Detection Using Blood Glucose Measurements

    Methods and devices to detect analyte in body fluid are provided. Embodiments include receiving one or more analyte sensor data, receiving a reference measurement value associated with an analyte level, determining a sensitivity parameter based on the received one or more analyte sensor data and the reference measurement value, performing a probability analysis based on prior analyte sensor data to determine presence of signal attenuation, and generating an output value based on the probability analysis.

  • Body Fluid Analyzing System and an Imaging Processing Device and Method for Analyzing Body Fluids

    The present invention discloses a body fluid analyzing system, comprising: a central control and processing component for sending a control signal to the source image capturing component; a source image capturing component for capturing a body fluid source image according to said control signal and sending said source image to said central control and processing component. Said central control and processing component is further used for transforming source images to image coefficients and generating the corresponding coefficient matrix. Then the coefficient matrix is inversely transformed to a focus-fused image for output. The present invention further discloses an image processing device and method for analyzing body fluid. The application of the present invention can reduce the probability of object image omission or fuzziness and, to a great extent, increase the identification success rate so that the precision of the entire system is increased.

  • Body Fluid Analyzing System and an Imaging Processing Device and Method for Analyzing Body Fluids

    The present invention discloses a body fluid analyzing system, comprising: a central control and processing component for sending a control signal to the source image capturing component; a source image capturing component for capturing a body fluid source image according to said control signal and sending said source image to said central control and processing component. Said central control and processing component is further used for transforming source images to image coefficients and generating the corresponding coefficient matrix. Then the coefficient matrix is inversely transformed to a focus-fused image for output. The present invention further discloses an image processing device and method for analyzing body fluid. The application of the present invention can reduce the probability of object image omission or fuzziness and, to a great extent, increase the identification success rate so that the precision of the entire system is increased.

  • body fluid detection method using surface enhanced Raman spectroscopy

    This invention provides a body fluid detection method by using surface enhanced Raman spectroscopy. In this method, some biological macromolecules in body fluid samples could be separated with membrane electrophoresis technique firstly. Next, samples are cut off along with the substrates and touched with glacial acetic acid. Transparent colloid formed while incubating. Then add enhancing substrates and continue to incubate and stir. When solid impurities precipitated, stop incubating and stand for layering. In the end, take upper layer resulted to be tested using SERS detection method and build SERS database. This invention successfully eliminated disturbance of other complex components on the SERS detection of protein, DNA and RNA. High quality SERS spectrum obtained is beneficial to the analysis and process of SERS spectrum. Thus body fluid can be differentiated by comparing body fluid SERS spectrum belonging to the healthy people and patients.

  • BODY FLUID ANALYSIS FIXTURE

    The present invention is intended to, in a configuration in which a liquid container for analysis sealed by a sealing member is penetrated by a penetrating member, prevent the sealing member from being unexpectedly broken to leak a liquid for analysis. Also, the present invention has: a container holder part that holds a liquid container for analysis; a penetrating member that penetrates a sealing member of the liquid container for analysis; a first moving mechanism that enables the penetrating member to be moved between a hole making position and a receding position; and a second moving mechanism that enables the penetrating member moved to the hole making position by the first moving mechanism to be moved toward the sealing member to a penetrating position where the penetrating member penetrates the sealing member.

  • Methods Of Renal Cancer Detection

    Disclosed are methods for detecting, diagnosing or monitoring a renal cancer in a subject. The methods include detecting quantity of one or more polypeptides or fragments thereof comprised by body fluid such as urine, wherein the one or more polypeptides or fragments thereof, can be present at elevated levels in a subject with a kidney cancer, as compared to a subject without a kidney cancer. Non-limiting examples of such polypeptides include aquaporin-1, adipose differentiation-related protein and paired box protein-2. Antibody probes can be used to detect or quantify the polypeptides. In some embodiments, mass spectroscopy can be used to detect or quantify the polypeptides, or to identify a polypeptide in a body fluid sample from a subject with a kidney cancer.

  • Detection of Cancer Cells in Body Fluids

    A method of detecting circulating melanoma or carcinoma cells in a subject. The method comprises obtaining a body fluid from a subject and detecting the expression of a panel of genes in the body fluid, wherein the expression of the panel of genes indicates the presence of circulating melanoma or carcinoma cells in the subject. Genes useful for detecting melanoma cells includes GalNAc-T, MAGE-A3, MART-1, PAX-3, and TRP-2; genes useful for detecting carcinoma cells include C-Met, MAGE-A3, Stanniocalcin-1, Stanniocalcin-2, mammaglobin, HSP27, GalNAc-T, CK20, and .beta.-HCG. Also disclosed are kits containing agents for detecting the expression of these genes.

  • METHODS AND KITS FOR DETECTING, DIAGNOSING AND MONITORING DISEASES

    The invention provides methods and kits for detecting metabolites in a body fluid by contacting a sample of the body fluid with at least one reducible dye at a pH-value which is higher than the pKa-value of the reducible dye, whereby a color change resulting from reduction of the reducible dye is indicative of the presence of metabolites in the body fluid. The methods and kits are of use in the detection and monitoring of disease conditions.

  • Method and a Kit to Detect Malignant Tumors and Provide a Prognosis

    A method and kit is provided to quantifying and qualifying exosomes in human cell derived samples or in body fluid based on expression of TM9-superfamily proteins on the exosomes. Furthermore, a method and a kit to diagnose malignant tumors is provided. The disclosure also provides a method to monitor tumor growth.

  • COEFFICENT DETERMINATION FOR BLOOD OXYGEN SATURATION AND TOTAL HEMOGLOBIN CONCENTRATION INDICES

    A first concentration of a chromophore corresponding to a measurement volume of an optical sensor is determined. A second concentration of the chromophore is obtained in the vicinity of the measurement volume corresponding to a change in at least one of a total concentration of the chromophore and a relative concentration of a first form of the chromophore to the total concentration of the chromophore in the measurement volume. Light remittance measurements including a first light wavelength and a second light wavelength are obtained corresponding to the first chromophore concentration and the second chromophore concentration. A coefficient for computing an index of a change in the chromophore concentration is computed using the difference between the first and second chromophore concentrations and the first and second light remittance measurements.

  • WHOLE BLOOD ASSAY FOR MEASURING AMPK ACTIVATION

    A method of sample analysis is provided. In certain embodiments, the method comprises: a) labeling cells of a blood sample using an antibody that specifically binds to phospho-AMPK or a phosphorylated target thereof, to produce a labeled sample; and b) measuring antibody binding by a population of blood cells of the labeled sample using flow cytometry. In particular embodiments, the method may further comprise, prior to the labeling step: contacting blood with a test agent ex vivo or in vivo; and comparing the evaluation to results obtained from a reference sample of blood cells.

  • WHOLE BLOOD ASSAY FOR MEASURING AMPK ACTIVATION

    A method of sample analysis is provided. In certain embodiments, the method comprises: a) labeling cells of a blood sample using an antibody that specifically binds to phospho-AMPK or a phosphorylated target thereof, to produce a labeled sample; and b) measuring antibody binding by a population of blood cells of the labeled sample using flow cytometry. In particular embodiments, the method may further comprise, prior to the labeling step: contacting blood with a test agent ex vivo or in vivo; and comparing the evaluation to results obtained from a reference sample of blood cells.

  • DIAGNOSIS OF LIVER PATHOLOGY THROUGH ASSESSMENT OF PROTEIN GLYCOSYLATION

    Methods for diagnosing pathology of the liver in a subject suspected of having such pathology are disclosed. The methods comprise quantifiably detecting lectin binding on proteins in biological fluids, and comparing the detected lectin binding with reference values for the binding of lectin of such proteins in healthy or disease states.

  • MATERIALS AND METHODS FOR MEASURING NITRIC OXIDE LEVELS IN BIOLOGICAL FLUIDS

    The subject invention presides novel devices and methods for the measurement of nitric oxide in biological samples, including wound fluid samples. These advantageous devices and methods can be used for clinicians to monitor the wound's nitric oxide metabolism and/or response to treatment.

  • Rapid Bed-Side Measurement of Neutrophil Elastase Activity in Biological Fluids

    The subject invention provides novel devices and methods for the detection and quantification of neutrophil elastase activity in biological samples.

  • REMOVAL OF OXYGEN FROM BIOLOGICAL FLUIDS

    A system for reducing the concentration of oxygen in a fluid including red blood cells includes a housing, a plurality of hollow tubes extending within the housing and adapted for flow of the fluid therethrough, wherein each tube includes an inlet and an outlet, and a carrier system that reduces the concentration of oxygen at an exterior surface of the tubes to facilitate transport of oxygen from the fluid flowing through the tubes to an exterior of the tubes.

  • REAGENT FOR BLOOD CELL COUNTING AND BLOOD ANALYSIS METHOD

    Disclosed is a novel reagent for blood cell counting and a novel blood analysis method, which enable blood cells such as leukocytes to be counted with high accuracy by dissociating platelet aggregates in capillary blood collected from a living body. The reagent for blood cell counting is used to dilute capillary blood collected from a living body to prepare a blood sample in order to count blood cells in the collected capillary blood using a particle analyzer, and is an aqueous solution containing a chloroquine salt.

  • BLOOD ANALYZER, BLOOD ANALYSIS METHOD, AND COMPUTER PROGRAM PRODUCT

    A blood analyzer, a blood analysis method, and a computer program product that can distinguishably detect abnormal lymphocytes, blasts, and atypical lymphocytes are provided. A blood analyzer prepares a first measurement sample from a first reagent containing a hemolyzing agent, a second reagent containing a fluorescence staining dye, and the blood specimen, and prepares a second measurement sample from a third reagent containing a hemolyzing agent, a fourth reagent containing a fluorescence staining dye, and the blood specimen. The blood analyzer measures each of the measurement samples, and distinguishably detects abnormal lymphocytes, blasts, and atypical lymphocytes in a blood specimen based on the measurement data.

  • DISPOSABLE CASSETTE AND METHOD OF USE FOR BLOOD ANALYSIS ON BLOOD ANALYZER

    A disposable cassette for blood analysis includes a housing having an upper panel and a sampling section having a filling inlet; at least one pair of chambers in a form of depression of the upper panel of the housing and sealed by a diaphragm; portions of the diaphragm over the chambers being flexible; and one or more channels adapted to interconnect the pair of chambers; one of the chambers containing a predetermined amount of a reagent for blood analysis; and a sample outlet disposed next to and connected to the chamber containing the reagent, the sample outlet including an outlet cavity recessed from the upper panel, a divider disposed therein, and a cover covering the outlet cavity; the sample outlet sealing the reagent to the chamber containing the reagent. Further disclosed is the method of using the disposable cassette for measurements of hematology parameters on a blood analyzer.

  • MICROFLUIDIC DEVICE PROVIDING DEGASSING DRIVEN FLUID FLOW

    A device for blood-plasma separation and plasma-based blood analysis is described. The device uses blood samples smaller than 5 .mu.L, (directly from the finger) and flow is achieved with a degassing-driven flow technique that causes blood to flow spontaneously into air-filled dead-end channels without external pumping mechanisms.

  • DISPOSABLE CASSETTE AND METHOD OF USE FOR BLOOD ANALYSIS ON BLOOD ANALYZER

    A disposable cassette for blood analysis includes a housing having an upper panel and a sampling section having a filling inlet; at least one pair of chambers in a form of depression of the upper panel of the housing and sealed by a diaphragm; portions of the diaphragm over the chambers being flexible; and one or more channels adapted to interconnect the pair of chambers; one of the chambers containing a predetermined amount of a reagent for blood analysis; and a sample outlet disposed next to and connected to the chamber containing the reagent, the sample outlet including an outlet cavity recessed from the upper panel, a divider disposed therein, and a cover covering the outlet cavity; the sample outlet sealing the reagent to the chamber containing the reagent. Further disclosed is the method of using the disposable cassette for measurements of hematology parameters on a blood analyzer.

  • HUMAN INSULIN ASSAY AND ASSAY REAGENT

    A problem of the present invention is to provide an antibody specific to human insulin and an assay and an assay reagent using the antibody capable of accurately assaying human insulin without being affected by porcine insulin. The present invention provides an assay and an assay reagent capable of specifically assaying human insulin by combining a monoclonal antibody specifically reactive with human insulin and nonreactive with porcine insulin and a different anti-human insulin antibody.

  • METHODS AND KITS FOR DECREASING INTERFERENCES IN PLASMA OR SERUM CONTAINING ASSAY SAMPLES OF SPECIFIC BINDING ASSAYS

    Methods and kits are provided for decreasing interferences and inaccuracies due to nonoptimal sample handling of blood samples in plasma or serum containing assay samples of specific binding assays by addition of a large polycation to the assay sample during the specific binding assay.

  • METHODS FOR PREDICTING PREGNANCY OUTCOME IN A SUBJECT BY HCG ASSAY

    The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present invention further provides a method for determining the amount of early pregnancy associated molecular isoforms of human chorionic gonadotropin (hCG) in a sample. The present invention also provides a diagnostic kit for determining the amount of early pregnancy associated hCG in a sample. The present invention additionally provides an antibody which specifically binds to an early pregnancy associated molecular isoform of human chorionic gonadotropin. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample.

  • System and method for monitoring at least one blood parameter

    The invention relates to a system and a method for monitoring at least one blood parameter of the blood from a predetermined patient, with an access device for setting up access to the patient's blood, a removal device for removing an amount of blood in order to obtain a blood sample, a blood analysis device for analysing the blood sample, and a calculation device for calculating drug parameters of a drug to be administered to the patient as well as a supply device for supplying the drug having the calculated drug parameters. The system identifies the blood samples using bar codes, as a result of which there are no errors when assigning the blood to be analysed to the respective patient.

  • ARRAY FOR DETECTING BIOLOGICAL SUBSTANCE, ASSAY SYSTEM AND ASSAY METHOD

    Provided are a device, whereby cells, a bacterium or a virus can be quantified in a single unit, an assay system and an assay method. A subject to be assayed such as cells, a bacterium or a virus, which are present on a sensor, can be quantified by using a sensor equipped with multiple electrodes, said electrodes being similar in size to the subject to be assayed, detecting, concerning each electrode, the presence or absence of the subject in the vicinity of the electrode, and adding up the electrodes in which the subject is detected.

  • BIOMARKER ASSAY OF NEUROLOGICAL CONDITION

    A process and assay for determining the neurological condition in a subject is provided whereby the level of one or more neuroactive biomarkers is measured in a sample obtained from the subject. The processes and assay include measurement of multiple neuroactive biomarkers for synergistic determination of a neurological condition such as neurological damage due to injury, disease, contact with a compound, or other source.

  • APPARATUS AND METHODS FOR PREPARATION AND ANALYSIS OF DRIED SAMPLES OF A BIOLOGICAL FLUID

    Described is a device for collecting a fluid sample, such as a biological fluid sample. The device includes a planar collection substrate having an absorbent material. The planar collection substrate includes an impermeable region and a sample collection region. The impermeable region is impermeable to the fluid sample and is embedded in the planar collection substrate in a spatial pattern. The sample collection region is in an area excluded from the spatial pattern and has a shape and a size defined by the spatial pattern. The sample collection region is configured to receive a known volume of the fluid sample. In an alternative form, the device includes a sample collection element disposed in an impermeable planar holder and, in another alternative form, the device includes an absorbent material disposed inside an impermeable tube wall.

  • METHOD FOR COLLECTING NUCLEATED RED BLOOD CELLS VIA DENSITY-GRADIENT CENTRIFUGATION UTILIZING CHANGES IN BLOOD CELL DENSITY

    This invention provides a method for concentrating and collecting small quantities of fetal nucleated red blood cells contained in the maternal blood. The method for concentrating and collecting nucleated red blood cells from the maternal blood comprises: (i) subjecting the maternal blood to a first density-gradient centrifugation and collecting a cell fraction containing nucleated red blood cells; (ii) treating the cell fraction containing nucleated red blood cells so as to selectively changes the density of the nucleated red blood cells from that of the white blood cells; and (iii) subjecting the treated cell fraction containing the nucleated red blood cells to a second density-gradient centrifugation so as to collect a fraction containing nucleated red blood cells.

  • METHODS FOR INCREASING RED BLOOD CELL LEVELS AND TREATING ANEMIA USING A COMBINATION OF GDF TRAPS AND ERYTHROPOIETIN RECEPTOR ACTIVATORS

    In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.

  • RAPID AND SENSITIVE DETECTION OF BACTERIA IN BLOOD PRODUCTS, URINE, AND OTHER FLUIDS

    The invention provides methods of detecting bacteria in fluids, including blood, platelets and other blood products for transfusion, and urine. The methods are based on lysing the bacteria to release ATP and detecting the ATP. Eukaryotic cell contamination is a problem to be overcome, because eukaryotic cell contain large amounts of ATP. Thus, some of the methods involve separating intact eukaryotic cells (e.g., platelets) from intact bacterial cells before lysing the bacterial cells to release ATP, contacting the ATP with an ATP-consuming enzyme that catalyzes a reaction, and monitoring the enzyme-catalyzed reaction. Typically, the enzyme is luciferin, and the reaction is monitored by detecting light produced by the luciferin. Other methods of the invention involve contacting a fluid sample with a support surface that binds bacterial cells, lysing the bacterial cells to release ATP, contacting the ATP with an ATP-consuming enzyme, and monitoring the enzyme-catalyzed reaction. Apparatuses for carrying out the methods are also disclosed.

  • URINE ANALYSIS METHOD, DEVICE THEREOF, PROGRAM USED IN URINE ANALYSIS METHOD, AND STORAGE MEDIUM THEREOF

    An analysis device includes determination means, capable of performing a first determination on whether a specific component in urine is positive or negative, on the basis of a color reaction between a reagent and the specific component in urine; and optical measurement means capable of working out data on light absorption characteristics of the urine itself with respect to light of a predefined wavelength region. When the data on the light absorption characteristics lies within a predefined range, and a result of the first determination is either positive or negative as established beforehand, the determination means changes the result of the first determination to a false positive or a false negative, or performs second determination to the effect that there is a likelihood of a false positive or a false negative.

  • COLORECTAL CANCER MARKER VITRONECTIN AND METHOD FOR ANALYZING VITRONECTIN CONCENTRATION IN BLOOD SAMPLE

    The present invention provides a tumor screening marker that can be actually used in clinical practice to detect colorectal cancer, and a tumor progression marker that can complement CEA or CA19-9. Vitronectin for use as a tumor progression marker, a tumor screening marker or a prognostic prediction marker for colorectal cancer. A method of analyzing a vitronectin concentration in a collected blood sample. In the method, a measured value of vitronectin and a reference value of vitronectin are compared. Vitronectin is preferably used in combination with existing marker for colorectal cancer such as carcinoembryonic antigen and CA19-9.

  • COLORECTAL CANCER MARKER GALECTIN, METHOD FOR ANALYZING GALECTIN CONCENTRATION IN BLOOD SAMPLE, AND KIT FOR DETECTING COLORECTAL CANCER MARKER GALECTIN

    The present invention provides a tumor screening marker that can be actually used in clinical practice to detect colorectal cancer, and a tumor progression marker that can complement CEA or CA19-9. Galectin-1 used as a tumor screening marker or a tumor progression marker for colorectal cancer. Galectin-3 used as a tumor screening marker. Galectin-4 used as a tumor progression marker, a tumor screening marker, or a prognostic prediction marker for colorectal cancer. A method of analyzing the galectin concentration in a collected blood sample using the galectin. A colorectal cancer marker detection kit comprising a detection antibody selected from the group consisting of a fluorescently labeled galectin-1 antibody, a fluorescently labeled galectin-3 antibody, and a fluorescently labeled galectin-4 antibody.

  • METHODS OF DETECTING PREGNANCY-ASSOCIATED PLASMA PROTEIN-A2 (PAPP-A2)

    The present invention provides pregnancy associated plasma protein A2 (PAPP-A2), its nucleotide and amino acid sequences, antisense molecules to the nucleotide sequences which encode PAPP-A2, expression vectors for the production of purified PAPP-A2, antibodies capable of binding specifically to PAPP-A2, hybridization probes or oligonucleotides for the detection of PAPP-A2-encoding nucleotide sequences, genetically engineered host cells for the expression of PAPP-A2, and methods for screening for pathologies in pregnant and non-pregnant patients. Methods for screening for altered focal proliferation states in pregnant and/or non-pregnant patients, which include detecting levels of PAPP-A2, are also described.

  • PREGNANCY-ASSOCIATED PLASMA PROTEIN-A2 (PAPP-A2) POLYNUCLEOTIDES

    The present invention provides pregnancy associated plasma protein A2 (PAPP-A2), its nucleotide and amino acid sequences antisense molecules to the nucleotide sequences which encode PAPP-A2, expression vectors for the production of purified PAPP-A2, antibodies capable of binding specifically to PAPP-A2, hybridization probes or oligonucleotides for the detection of PAPP-A2-encoding nucleotide sequences, genetically engineered host cells for the expression of PAPP-A2, and methods for screening for pathologies in pregnant and non-pregnant patients. Methods for screening for altered focal proliferation states in pregnant and/or non-pregnant patients, which include detecting levels of PAPP-A2, are also described.

  • SERUM SPLA2-IIA AS DIAGNOSIS MARKER FOR PROSTATE AND LUNG CANCER

    Kits for assessing lung cancer in patients with solitary pulmonary nodules and methods for assessing lung cancer. The kit includes reagents for detection and/or quantification of serum secretory phospholipase A.sub.2-IIA in plasma, reagents for detection and/or quantification of carcinoembryonic antigen in plasma, and reagents for detection and/or quantification of cytokeratin-19 fragment in plasma. The method includes contacting a sample with a specific binding agent for serum secretory phospholipase A.sub.2-IIA, a specific binding agent for carcinoembryonic antigen, and a specific binding agent for cytokeratin-19 fragment, calculating levels of serum secretory phospholipase A.sub.2-IIA, carcinoembryonic antigen, and cytokeratin-19 fragment, and assessing as indicating lung cancer in the patient if the calculated levels are elevated.

  • METHOD OF DETECTING TAU PROTEIN AND TAU FRAGMENTS IN SERUM

    The present invention provides quantitative methods for the detection of tau protein and/or tau fragments. More specifically, the present invention provides quantitative methods for diagnosing a tauopathy or ruling out a tauopathy as the cause of disease, particularly the diagnosis and ruling of Alzheimer's disease. The present invention further provides a method for diagnosing a tauopathy by computing the ratio of two detected tau proteins or tau fragments.

  • METHOD FOR THE CULTIVATION OF PRIMARY CELLS AND FOR THE AMPLIFICATION OF VIRUSES UNDER SERUM FREE CONDITIONS

    The present invention relates to a method for the cultivation of primary cells. The primary cells are cultivated in a serum free medium comprising a factor selected from the group consisting of growth factors and attachment factors. The method for the cultivation of primary cells may be one step in a method for the amplification of viruses, such as poxviruses. According to this latter method the primary cells are cultivated in a serum free medium comprising a factor selected from the group consisting of growth factors and attachment factors. The cells are then infected with the virus and the infected cells are cultivated in serum free medium until progeny virus is produced.

  • COMPOSITIONS AND METHODS FOR INCREASING SERUM HALF-LIFE

    Provided herein are glycovariant Fc fusion proteins having increased serum half lives. Also provided are methods for increasing the serum half life of an Fc fusion protein by introducing one or more non-endogenous glycosylation sites.

  • CHOLESTEROL LOWERING AGENT, NEUTRAL FAT LOWERING AGENT, BLOOD GLUCOSE LEVEL LOWERING AGENT, CHOLESTEROL ADSORBENT, ADSORBENT, NEUTRAL FAT ADSORBENT, HEALTHY FOOD, HEALTH SUPPLEMENT, FOOD WITH NUTRIENT FUNCTION CLAIMS, FOOD FOR SPECIFIED HEALTH USE, QUASI-DRUG, AND PHARMACEUTICAL DRUG

    [Object] To provide a cholesterol lowering agent, a neutral fat lowering agent, a blood glucose level lowering agent, a cholesterol adsorbent, and a neutral fat adsorbent, which have high safety. [Solving Means] A cholesterol lowering agent, a neutral fat lowering agent, a blood glucose level lowering agent, a cholesterol adsorbent, and a neutral fat adsorbent include a porous carbon material having a specific surface area value of 10 m.sup.2/g or more and a pore volume of 0.1 cm.sup.3/g or more, the specific surface area value being measured by a nitrogen BET method, the pore volume being measured by a BJH method and an MP method.

  • APPARATUS AND METHOD FOR SEPARATING AND CONCENTRATING FLUIDS CONTAINING MULTIPLE COMPONENTS

    An apparatus that allows for separating and collecting a fraction of a sample. The apparatus, when used with a centrifuge, allows for the creation of at least three fractions in the apparatus. It also provides for a new method of extracting the buffy coat phase from a whole blood sample. A buoy system that may include a first buoy portion and a second buoy member operably interconnected may be used to form at least three fractions from a sample during a substantially single centrifugation process. Therefore, the separation of various fractions may be substantially quick and efficient.

  • BLOOD INSULIN RESISTANCE AND DIABETES MARKER PROGRANULIN, METHOD FOR ANALYZING CONCENTRATION OF PROGRANULIN IN BLOOD SAMPLE, AND METHOD FOR SCREENING FOR SUBSTANCE THAT IMPROVES INSULIN RESISTANCE AND IMPROVES OR SUPPRESSES DIABETES

    The present invention provides a marker capable of detecting insulin resistance and diabetes in a collected blood sample, a method for analyzing said marker, a method for screening a substance improving insulin resistance, and improving or suppressing diabetes. A blood insulin resistance marker and a blood diabetes marker, which comprises a polypeptide comprising at least 15 continuous amino acids in an amino acid sequence constituting progranulin. A method for analyzing a blood marker, which comprises the steps of: measuring a concentration of an insulin resistance marker or a diabetes marker in a collected blood sample; and comparing the measured concentration with a normal blood concentration of the marker. A method for screening a substance improving insulin resistance, and improving or suppressing diabetes, which comprises the steps of: administering a candidate substance to a living body expressing insulin resistance or suffering from diabetes; measuring a blood concentration of a marker in the living body after administration; and comparing the measured concentration of the marker with a blood concentration of the marker not administered with the candidate substance.

  • USE OF SPIRONOLACTONE-BASED COMPOSITION THAT EXHIBITS AN INHIBITORY ACTION ON T-LYMPHOCYTE ACTIVATION WHICH IS USEFULE FOR PREVENTING AND/OR TREATING MULTIPLE SCLEROSIS

    The present invention relates to the use of spironolactone for the preparation of a pharmaceutical composition intended for preventing and/or treating multiple sclerosis. Alternatively, the invention relates to the use of spironolactone directly in T-lymphocytes or dendritic cells obtained from a blood sample taken from a patient and then injected back into the circulation. Therefore, the present invention relates to the use of a composition comprising spironolactone that can be used in the treatment of multiple sclerosis, which covers the administration of spironolactone directly or lymphocytes pre-treated with spironolactone, or dendritic cells to individuals requiring such treatment. Spironolactone is an orally administered drug that is less expensive than many of the treatments available for MS and, furthermore, has the advantage of being a known compound already used in humans for extended periods and therefore the adverse effects thereof have been described in clinical studies.

  • METHOD FOR PREDICTING A NEED FOR RENAL REPLACEMENT THERAPY (RRT)

    A method for predicting a need for Renal Replacement Therapy (RRT) in a patient comprises: determining a concentration of pi glutathione S transferase-(.pi.GST) in a first urine sample from the patient; and wherein a need for RRT is predicted when the .pi.GST concentration is determined to be elevated in comparison to a patient without kidney injury. The method according to the invention can further comprise detecting for the presence of risk factors for RRT in a patient, the risk factors including elevated serum creatinine concentration, type I diabetes, type II diabetes, hypertension, dyslipidemia, hyperglycaemia, proteinuria and hypoalbuminemia.

  • USE OF URINARY NGAL TO DIAGNOSE UNILATERAL AND BILATERAL URINARY OBSTRUCTION

    In one embodiment, the present invention is directed to methods for diagnosis of urinary tract obstruction (UTO), and to methods for distinguishing between unilateral and bilateral UTO. In some aspects, the diagnostic methods of the invention are based on determining whether a bodily fluid sample, such as a urine sample, contains an amount of NGAL protein that exceeds or is less than a certain threshold level, or that falls within a certain range. The present invention also provides diagnostic kits for the diagnosis of UTO and for distinguishing between unilateral and bilateral UTO.

  • DETECTING DNA METHYLATION OF BCL2, CDKN2A AND NID2 GENES TO PREDICT BLADDER CANCER IN HUMANS

    The present invention provides a method of detecting DNA methylation of a plurality of genes consisting of CDKN2A, BCL2 and NID2 in a urine sample from a human. Methods and compositions are provided herein for detecting and diagnosing bladder cancer by obtaining a urine sample from a human subject suspected of bladder cancer, followed by detecting DNA methylation of CDKN2A, BCL2 AND NID2 in urine samples from the individual. The present method permits specific detection of DNA methylation of the selected gene promoters in urine as a biomarker for bladder cancer in humans.

  • URINE ANALYZER AND URINE SAMPLE INFORMATION PROCESSING METHOD

    A urine analyzer includes a controller configured to perform, when a qualitative measurement result of a sample is obtained and a sediment measurement result of the sample has been stored in a storage section, a cross-check of the obtained qualitative measurement result and the stored sediment measurement result, and to perform, when a sediment measurement result of a sample is obtained and a qualitative measurement result of the sample has been stored in the storage section, a cross-check of the obtained sediment measurement result and the stored qualitative measurement result.

  • METHOD FOR THE EARLY IDENTIFICATION AND PREDICTION OF AN ABRUPT REDUCTION IN KIDNEY FUNCTION IN A PATIENT UNDERGOING CARDIOTHORACIC SURGERY

    A method for the early identification and prediction of abrupt reduction in kidney function in a patient undergoing cardiothoracic (CT) surgery, including Cardio-Pulmonary Bypass (CPB), comprises contacting a urine sample from the patient with a capture molecule for a biomarker, especially .pi.GST specific for the distal region of the renal tubule and which biomarker is released from said region when there is damage to said region indicative and predictive of an abrupt reduction in kidney function, the biomarker being detectable as early as intraoperatively or in the recovery stage post CT surgery, for example prior to transfer of the patient to the Intensive Care Unit (ICU), allowing for immediate corrective medical intervention. The method can be used to detect Acute Kidney Injury (AKI) and a requirement for Renal Replacement Therapy (RRT) namely dialysis, earlier than two hours post CT surgery and as early as zero hours post or during CT surgery or CPB.

  • ASSAYS AND METHODS OF TREATMENT RELATING TO VITAMIN D INSUFFICIENCY

    Described herein are assays directed to determining the level of bioavailable or free vitamin D in a blood sample in a subject. The values determined for bioavailable or free vitamin D indicate whether the subject suffers from insufficient levels of vitamin D. Also described herein are methods of treatment for vitamin D insufficiency.

  • METHOD OF REGULATING PLASMA LIPOPROTEINS

    A method of modulating the level of lipoproteins in human cells comprising the step of inhibiting resistin in the cells or cellular environment. The method is useful to treat cardiovascular disease.

  • METHOD FOR PREDICTING THE RESPONSE TO A TREATMENT AGAINST HEPATITIS C

    The invention relates to a method for predicting the response to an interferon-based treatment in a patient infected with hepatitis C virus. This method consists in determining the presence of apolipoprotein CIII and/or of a multimeric form of human serum albumin in a sample of biological fluid from the patient.

  • METHODS AND COMPOSITIONS FOR DIAGNOSIS, STRATIFICATION, AND MONITORING OF ALZHEIMER'S DISEASE AND OTHER NEUROLOGICAL DISORDERS IN BODY FLUIDS

    The inventors have discovered a collection of proteinaceous biomarkers ("AD biomarkers) which can be measured in peripheral biological fluid samples to aid in the diagnosis of neurodegenerative disorders, particularly Alzheimer's disease and mild cognitive impairment (MCI). The invention further provides methods of identifying candidate agents for the treatment of Alzheimer's disease by testing prospective agents for activity in modulating AD biomarker levels.

  • COMPOSITE OF HERBAL EXTRACTS FOR LOWERING BLOOD LIPID AND MEDICATION COMPRISING THE SAID COMPOSITE

    A composite of herbal extracts comprises an extract of Eucheuma okamurai Yamada in a weight ratio of 33.4%-77.7%; an extract of Acanthopanax senticosus in a weight ratio of 11.14%-33.3%; and an extract of Dioscorea alata in a weight ratio of 11.14%-33.3%. Furthermore, a medication for lowering blood lipid, comprising the said composite of herbal extracts and a pharmaceutical acceptable carrier or excipient, is also disclosed.

  • THERAPY PREDICTION AND OPTIMIZATION OF SERUM POTASSIUM FOR RENAL FAILURE BLOOD THERAPY, ESPECIALLY HOME HEMODIALYSIS

    A method of predicting serum potassium concentrations in a patient during hemodialysis includes measuring serum potassium concentrations of the patient over a hemodialysis treatment session time and an ultrafiltration rate calculated by a difference between pre- and post-dialytic body weight of the patient during an initial hemodialysis treatment session divided by a total treatment time of the treatment session and estimating a potassium mobilization clearance and a pre-dialysis distribution volume of potassium for the patient. Serum potassium concentrations of the patient can then be predicted at any time during any hemodialysis treatment session with the estimated potassium mobilization clearance and pre-dialysis distribution volume of potassium of the patient.

  • THERAPEUTIC RETRIEVAL OF TARGETS IN BIOLOGICAL FLUIDS

    Method and apparatus for removing high density particles from a biological fluid such as blood using aphaeresis. The particles are preferably sub-micron in size and denser than normally occurring components of the fluid and can be removed by a modified reverse-flow gradient density centrifuge without damaging the fluid. The particles can be provided to a patient in vivo or added to the fluid after it is removed from the patient. Some particles can carry and deliver oxygen and scavenge carbon dioxide. Other particles are conjugated to capture molecules for attaching to targets such as cancer cells, viruses, pathogens, toxins, or excess concentrations of a drug or element in the fluid. The targets are then removed from the fluid along with the particles by the aphaeresis instrument.